RAB3IL1
gene geneOn this page
Also known as GRAB
Summary
RAB3IL1 (RAB3A interacting protein like 1, HGNC:9780) is a protein-coding gene on chromosome 11q12.2-q12.3, encoding Guanine nucleotide exchange factor for Rab-3A (Q8TBN0). Guanine nucleotide exchange factor (GEF) which may activate RAB3A, a GTPase that regulates synaptic vesicle exocytosis.
This gene encodes a guanine nucleotide exchange factor for the ras-related protein Rab3A. The encoded protein binds Rab3a and the inositol hexakisphosphate kinase InsP6K1. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 7.
Source: NCBI Gene 5866 — RefSeq curated summary.
At a glance
- GWAS associations: 16
- Clinical variants (ClinVar): 82 total
- MANE Select transcript:
NM_013401
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:9780 |
| Approved symbol | RAB3IL1 |
| Name | RAB3A interacting protein like 1 |
| Location | 11q12.2-q12.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | GRAB |
| Ensembl gene | ENSG00000167994 |
| Ensembl biotype | protein_coding |
| OMIM | 621025 |
| Entrez | 5866 |
Gene structure
Transcript identifiers
Ensembl transcripts: 14 — 12 protein_coding, 2 retained_intron
ENST00000301773, ENST00000394836, ENST00000526200, ENST00000530888, ENST00000531922, ENST00000533136, ENST00000867933, ENST00000867934, ENST00000867935, ENST00000867936, ENST00000867937, ENST00000923689, ENST00000964391, ENST00000964392
RefSeq mRNA: 2 — MANE Select: NM_013401
NM_001271686, NM_013401
CCDS: CCDS60809, CCDS8014
Canonical transcript exons
ENST00000394836 — 10 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001119132 | 61907565 | 61907660 |
| ENSE00001119133 | 61899314 | 61899380 |
| ENSE00001119134 | 61904754 | 61904882 |
| ENSE00001119135 | 61907393 | 61907470 |
| ENSE00001119136 | 61904546 | 61904658 |
| ENSE00001119139 | 61902442 | 61902541 |
| ENSE00001119140 | 61906466 | 61906684 |
| ENSE00001327994 | 61917357 | 61917566 |
| ENSE00001335610 | 61908054 | 61908306 |
| ENSE00002178705 | 61897301 | 61898360 |
Expression profiles
Bgee: expression breadth ubiquitous, 236 present calls, max score 93.01.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.8928 / max 85.5147, expressed in 1299 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 120056 | 4.3923 | 1257 |
| 120058 | 0.3258 | 72 |
| 120053 | 0.0623 | 18 |
| 120055 | 0.0586 | 18 |
| 120054 | 0.0538 | 20 |
Top tissues by expression
269 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| type B pancreatic cell | CL:0000169 | 93.01 | silver quality |
| tibial nerve | UBERON:0001323 | 92.10 | gold quality |
| left testis | UBERON:0004533 | 92.07 | gold quality |
| right testis | UBERON:0004534 | 92.04 | gold quality |
| right ovary | UBERON:0002118 | 91.97 | gold quality |
| endocervix | UBERON:0000458 | 91.92 | gold quality |
| apex of heart | UBERON:0002098 | 91.24 | gold quality |
| body of uterus | UBERON:0009853 | 91.13 | gold quality |
| left ovary | UBERON:0002119 | 90.85 | gold quality |
| mucosa of stomach | UBERON:0001199 | 90.44 | gold quality |
| olfactory bulb | UBERON:0002264 | 90.34 | silver quality |
| testis | UBERON:0000473 | 89.53 | gold quality |
| omental fat pad | UBERON:0010414 | 89.14 | gold quality |
| peritoneum | UBERON:0002358 | 89.10 | gold quality |
| left uterine tube | UBERON:0001303 | 88.83 | gold quality |
| sural nerve | UBERON:0015488 | 88.26 | gold quality |
| spleen | UBERON:0002106 | 88.12 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 88.00 | gold quality |
| ectocervix | UBERON:0012249 | 86.91 | gold quality |
| ovary | UBERON:0000992 | 86.52 | gold quality |
| right atrium auricular region | UBERON:0006631 | 86.08 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 86.01 | silver quality |
| subcutaneous adipose tissue | UBERON:0002190 | 85.71 | gold quality |
| cardiac atrium | UBERON:0002081 | 85.41 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 85.00 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 84.99 | gold quality |
| left coronary artery | UBERON:0001626 | 84.88 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 84.82 | gold quality |
| lower esophagus | UBERON:0013473 | 84.73 | gold quality |
| coronary artery | UBERON:0001621 | 84.66 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 5.42 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
39 targeting RAB3IL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4725-3P | 99.96 | 69.53 | 2520 |
| HSA-MIR-6780B-5P | 99.96 | 69.60 | 2562 |
| HSA-MIR-6825-5P | 99.96 | 69.81 | 3431 |
| HSA-MIR-4271 | 99.88 | 68.32 | 2244 |
| HSA-MIR-4728-5P | 99.85 | 69.39 | 4718 |
| HSA-MIR-1321 | 99.84 | 65.30 | 1811 |
| HSA-MIR-4739 | 99.84 | 65.25 | 1832 |
| HSA-MIR-4756-5P | 99.84 | 64.98 | 1809 |
| HSA-MIR-6785-5P | 99.82 | 68.68 | 4428 |
| HSA-MIR-6756-5P | 99.82 | 67.97 | 2466 |
| HSA-MIR-3121-3P | 99.82 | 71.96 | 3630 |
| HSA-MIR-6794-5P | 99.76 | 66.38 | 1048 |
| HSA-MIR-149-3P | 99.72 | 68.22 | 3963 |
| HSA-MIR-6883-5P | 99.69 | 68.05 | 3785 |
| HSA-MIR-4716-3P | 99.69 | 66.73 | 1022 |
| HSA-MIR-6766-5P | 99.68 | 67.70 | 2325 |
| HSA-MIR-6887-3P | 99.66 | 67.83 | 1778 |
| HSA-MIR-7106-5P | 99.53 | 67.47 | 3574 |
| HSA-MIR-5580-5P | 99.38 | 66.96 | 1139 |
| HSA-MIR-149-5P | 99.25 | 67.16 | 1315 |
| HSA-MIR-4651 | 99.06 | 67.57 | 2002 |
| HSA-MIR-6737-3P | 98.95 | 68.56 | 1577 |
| HSA-MIR-7157-3P | 98.95 | 68.70 | 1582 |
| HSA-MIR-3127-3P | 98.94 | 67.34 | 1055 |
| HSA-MIR-608 | 98.93 | 67.83 | 2013 |
| HSA-MIR-760 | 98.81 | 66.65 | 1392 |
| HSA-MIR-4763-5P | 98.75 | 63.89 | 854 |
| HSA-MIR-7113-3P | 98.75 | 65.71 | 1120 |
| HSA-MIR-5008-3P | 98.73 | 67.50 | 1433 |
| HSA-MIR-7155-5P | 98.65 | 66.14 | 1290 |
Literature-anchored findings (GeneRIF, showing 3)
- Intermediates in the guanine nucleotide exchange reaction of Rab8 protein catalyzed by guanine nucleotide exchange factors Rabin8 and GRAB. (PMID:24072714)
- Rab27/Rabphilin3a/GRAB/Rab3 constitutes a signaling module in sperm exocytosis. (PMID:30599141)
- Identification of hub genes in unstable atherosclerotic plaque by conjoint analysis of bioinformatics. (PMID:33011223)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rab3il1 | ENSDARG00000007711 |
| mus_musculus | Rab3il1 | ENSMUSG00000024663 |
| rattus_norvegicus | Rab3il1 | ENSRNOG00000020349 |
| caenorhabditis_elegans | WBGENE00010045 |
Paralogs (1): RAB3IP (ENSG00000127328)
Protein
Protein identifiers
Guanine nucleotide exchange factor for Rab-3A — Q8TBN0 (reviewed: Q8TBN0)
Alternative names: Rab-3A-interacting-like protein 1, Rabin3-like 1
All UniProt accessions (3): E9PK89, Q8TBN0, H0YD19
UniProt curated annotations — full annotation on UniProt →
Function. Guanine nucleotide exchange factor (GEF) which may activate RAB3A, a GTPase that regulates synaptic vesicle exocytosis. Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form. May also activate RAB8A and RAB8B.
Subunit / interactions. Interacts with RAB3A and IHPK1 through the coiled-coil domain. This interaction is competitive. IHPK1 kinase activity is not required for this interaction.
Similarity. Belongs to the SEC2 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q8TBN0-1 | 1 | yes |
| Q8TBN0-2 | 2 |
RefSeq proteins (2): NP_001258615, NP_037533* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR009449 | Sec2_N | Domain |
| IPR040351 | RAB3IL/RAB3IP/Sec2 | Family |
Pfam: PF06428, PF25555
UniProt features (14 total): compositionally biased region 3, region of interest 2, splice variant 2, sequence variant 2, modified residue 2, chain 1, helix 1, coiled-coil region 1
Structure
Experimental structures (PDB)
1 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 4LI0 | X-RAY DIFFRACTION | 3.3 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8TBN0-F1 | 79.83 | 0.60 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2): 168, 179
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-8876198 | RAB GEFs exchange GTP for GDP on RABs |
MSigDB gene sets: 142 (showing top):
GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, REACTOME_MEMBRANE_TRAFFICKING, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5, MYCMAX_01, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, USF_01, USF_02, BURTON_ADIPOGENESIS_10, SHEN_SMARCA2_TARGETS_DN, GOMF_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY, USF2_Q6, MYC_Q2, MYCMAX_03, MAX_01, ARNT_01
GO Biological Process (1): protein transport (GO:0015031)
GO Molecular Function (3): guanyl-nucleotide exchange factor activity (GO:0005085), identical protein binding (GO:0042802), protein binding (GO:0005515)
GO Cellular Component (1): cytosol (GO:0005829)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Rab regulation of trafficking | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| transport | 1 |
| intracellular protein localization | 1 |
| establishment of protein localization | 1 |
| GTP binding | 1 |
| GDP binding | 1 |
| GTPase regulator activity | 1 |
| protein binding | 1 |
| binding | 1 |
| cytoplasm | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
980 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RAB3IL1 | A2M | P01023 | 949 |
| RAB3IL1 | IP6K1 | Q92551 | 801 |
| RAB3IL1 | RAB3A | P20336 | 698 |
| RAB3IL1 | RAB11A | P24410 | 686 |
| RAB3IL1 | RAB8A | P24407 | 643 |
| RAB3IL1 | RABGEF1 | Q9UJ41 | 606 |
| RAB3IL1 | ARF1 | P10947 | 598 |
| RAB3IL1 | RAB8B | Q92930 | 586 |
| RAB3IL1 | TRIP11 | Q15643 | 570 |
| RAB3IL1 | RPH3A | Q9Y2J0 | 517 |
| RAB3IL1 | RAB40AL | P0C0E4 | 516 |
| RAB3IL1 | CASP3 | P42574 | 509 |
| RAB3IL1 | ANKRD27 | Q96NW4 | 508 |
| RAB3IL1 | RAB32 | Q13637 | 501 |
| RAB3IL1 | RAB21 | Q9UL25 | 498 |
IntAct
111 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| RAB3IL1 | RAB3IP | psi-mi:“MI:0915”(physical association) | 0.890 |
| RAB3IP | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.890 |
| RAB3IP | TRAPPC3 | psi-mi:“MI:0914”(association) | 0.700 |
| NOTCH2NLA | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.670 |
| RAB3IL1 | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.670 |
| RAB3IL1 | NOTCH2NLA | psi-mi:“MI:0915”(physical association) | 0.670 |
| RAB3IL1 | MTUS2 | psi-mi:“MI:0915”(physical association) | 0.670 |
| MTUS2 | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.670 |
| RAB3IL1 | NUDT18 | psi-mi:“MI:0915”(physical association) | 0.620 |
| RAB3IL1 | TIGD7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RAB3IL1 | PSMA3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CCDC57 | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MTUS2 | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRT40 | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SATB2 | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TIGD7 | RAB3IL1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RAB3IL1 | CCDC57 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (90): RAB3IL1 (Two-hybrid), RAB3IL1 (Two-hybrid), MTUS2 (Two-hybrid), SATB2 (Two-hybrid), TIGD7 (Two-hybrid), RAB3IP (Two-hybrid), KRT40 (Two-hybrid), CCDC57 (Two-hybrid), NOTCH2NL (Two-hybrid), RAB3IL1 (Biochemical Activity), RAB3IP (Affinity Capture-MS), TMEM102 (Affinity Capture-MS), PPFIA3 (Affinity Capture-MS), ATG4C (Affinity Capture-MS), AMOTL1 (Affinity Capture-MS)
ESM2 similar proteins: A0A1B0GU71, A6QPI4, B2RV13, D4A6L0, E1BBQ2, F1LQY6, G3UW36, O08856, P15382, P53801, P55199, P56182, Q08CB3, Q0VF94, Q148E1, Q17RQ9, Q2KJ58, Q32Q90, Q4R5F9, Q4V8A6, Q4VA36, Q5I0I4, Q5NVI6, Q5R8Q2, Q5T6X4, Q5T848, Q5XII8, Q68EN5, Q6P767, Q8C419, Q8CHT6, Q8R143, Q8R1T1, Q8TBN0, Q8VDV3, Q8WUX9, Q90YH8, Q91WM6, Q91ZP9, Q96IL0
Diamond homologs: O13930, Q2KJ58, Q4WWM8, Q5AL49, Q8TBN0, Q62739, Q68EF0, Q8VDV3, Q96QF0, Q99NH3
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| “Elongator complex” | “up-regulates activity” | RAB3IL1 | binding |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 46 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| RAB GEFs exchange GTP for GDP on RABs | 8 | 34.2× | 7e-09 |
| COPII-mediated vesicle transport | 6 | 33.8× | 1e-06 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| obsolete vesicle tethering | 6 | 156.5× | 1e-10 |
| endoplasmic reticulum to Golgi vesicle-mediated transport | 6 | 21.5× | 2e-05 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
82 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 69 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1886 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 11:61899273:C:CA | donor_gain | 1.0000 |
| 11:61899312:ACCGT:A | donor_gain | 1.0000 |
| 11:61899313:CCGTC:C | donor_gain | 1.0000 |
| 11:61902436:ACTC:A | donor_loss | 1.0000 |
| 11:61902437:CTCA:C | donor_loss | 1.0000 |
| 11:61902438:TCA:T | donor_loss | 1.0000 |
| 11:61902439:CACCC:C | donor_loss | 1.0000 |
| 11:61902440:A:AC | donor_gain | 1.0000 |
| 11:61902440:AC:A | donor_gain | 1.0000 |
| 11:61902441:C:CC | donor_gain | 1.0000 |
| 11:61902441:C:CG | donor_loss | 1.0000 |
| 11:61902441:CC:C | donor_gain | 1.0000 |
| 11:61902537:ATGTG:A | acceptor_gain | 1.0000 |
| 11:61902538:TGTG:T | acceptor_gain | 1.0000 |
| 11:61902539:GTG:G | acceptor_gain | 1.0000 |
| 11:61902540:TG:T | acceptor_gain | 1.0000 |
| 11:61902542:C:CC | acceptor_gain | 1.0000 |
| 11:61904540:G:C | donor_gain | 1.0000 |
| 11:61904541:CTTA:C | donor_loss | 1.0000 |
| 11:61904542:TTA:T | donor_loss | 1.0000 |
| 11:61904543:TACT:T | donor_loss | 1.0000 |
| 11:61904544:A:AC | donor_gain | 1.0000 |
| 11:61904544:A:C | donor_loss | 1.0000 |
| 11:61904545:C:CC | donor_gain | 1.0000 |
| 11:61904545:CTTG:C | donor_gain | 1.0000 |
| 11:61904656:GAG:G | acceptor_gain | 1.0000 |
| 11:61904656:GAGC:G | acceptor_loss | 1.0000 |
| 11:61904657:AGCT:A | acceptor_loss | 1.0000 |
| 11:61904658:GC:G | acceptor_loss | 1.0000 |
| 11:61904659:C:CC | acceptor_gain | 1.0000 |
AlphaMissense
2470 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 11:61907446:C:G | A129P | 0.999 |
| 11:61907568:A:C | F119L | 0.999 |
| 11:61907568:A:T | F119L | 0.999 |
| 11:61907570:A:G | F119L | 0.999 |
| 11:61907584:A:G | L114P | 0.999 |
| 11:61906653:A:G | L157S | 0.998 |
| 11:61906669:C:G | A152P | 0.998 |
| 11:61907569:A:C | F119C | 0.998 |
| 11:61907593:A:G | L111P | 0.998 |
| 11:61906674:A:G | L150P | 0.997 |
| 11:61907404:C:G | A143P | 0.997 |
| 11:61906644:A:G | L160P | 0.996 |
| 11:61906656:G:T | A156D | 0.996 |
| 11:61906657:C:G | A156P | 0.996 |
| 11:61907614:C:G | R104P | 0.996 |
| 11:61898327:C:G | R367P | 0.995 |
| 11:61902449:C:G | R331P | 0.995 |
| 11:61902464:A:T | I326N | 0.995 |
| 11:61904849:A:G | W231R | 0.995 |
| 11:61904849:A:T | W231R | 0.995 |
| 11:61906641:A:T | V161D | 0.995 |
| 11:61906649:C:A | K158N | 0.995 |
| 11:61906649:C:G | K158N | 0.995 |
| 11:61907570:A:T | F119I | 0.995 |
| 11:61907572:A:G | L118P | 0.995 |
| 11:61907579:C:G | A116P | 0.995 |
| 11:61907605:A:G | L107P | 0.995 |
| 11:61899346:C:G | R345P | 0.994 |
| 11:61904618:A:T | L276H | 0.994 |
| 11:61907412:A:G | L140P | 0.994 |
dbSNP variants (sampled 300 via entrez): RS1000057770 (11:61929174 C>T), RS1000113162 (11:61906514 C>A,T), RS1000253539 (11:61936602 A>G), RS1000266218 (11:61918321 T>C), RS1000284636 (11:61936884 A>G), RS1000327429 (11:61901267 A>C), RS1000446613 (11:61905242 C>T), RS1000507372 (11:61930198 G>A), RS1000637785 (11:61906281 C>G), RS1000870236 (11:61919693 T>C), RS1000882851 (11:61925350 G>C), RS1000893539 (11:61901049 A>C), RS1000896941 (11:61919472 C>G,T), RS1000913882 (11:61924976 G>A), RS1000924446 (11:61907153 A>C)
Disease associations
OMIM: gene MIM:621025 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
16 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST001178_15 | Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid) | 2.000000e-17 |
| GCST001179_20 | Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid) | 3.000000e-35 |
| GCST001180_6 | Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid) | 1.000000e-12 |
| GCST001834_5 | Oleic acid (18:1n-9) levels | 2.000000e-32 |
| GCST002444_5 | Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid) | 5.000000e-168 |
| GCST002448_6 | Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid) | 4.000000e-140 |
| GCST002449_6 | Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid) | 0.000000e+00 |
| GCST002449_8 | Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid) | 7.000000e-147 |
| GCST002450_8 | Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid) | 2.000000e-72 |
| GCST002712_2 | Red blood cell fatty acid levels | 8.000000e-90 |
| GCST002712_4 | Red blood cell fatty acid levels | 3.000000e-305 |
| GCST002712_9 | Red blood cell fatty acid levels | 6.000000e-43 |
| GCST009391_2118 | Metabolite levels | 4.000000e-11 |
| GCST009391_407 | Metabolite levels | 9.000000e-13 |
| GCST90002406_370 | Reticulocyte fraction of red cells | 9.000000e-12 |
| GCST90011899_120 | Aspartate aminotransferase levels | 2.000000e-09 |
EFO canonical traits (10, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007760 | eicosapentaenoic acid measurement |
| EFO:0006809 | docosapentaenoic acid measurement |
| EFO:0007759 | alpha-linolenic acid measurement |
| EFO:0005680 | omega-6 polyunsaturated fatty acid measurement |
| EFO:0006808 | arachidonic acid measurement |
| EFO:0006811 | linolenic acid measurement |
| EFO:0006807 | linoleic acid measurement |
| EFO:0010382 | phosphatidylcholine 36:4 measurement |
| EFO:0010387 | phosphatidylcholine 38:5 measurement |
| EFO:0004736 | aspartate aminotransferase measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
44 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Arsenic | increases expression, affects cotreatment, decreases expression, increases abundance | 3 |
| bisphenol A | affects cotreatment, increases methylation, increases expression | 2 |
| sodium arsenite | affects cotreatment, increases abundance, increases expression | 2 |
| (+)-JQ1 compound | decreases expression | 2 |
| Benzo(a)pyrene | affects methylation, increases expression | 2 |
| Cisplatin | affects expression, decreases expression | 2 |
| FR900359 | decreases phosphorylation | 1 |
| methyleugenol | increases expression | 1 |
| sodium arsenate | increases abundance, increases expression | 1 |
| beta-lapachone | increases expression | 1 |
| o,p’-DDT | increases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | increases expression | 1 |
| boron nitride | increases expression | 1 |
| 3,4,5,3’,4’-pentachlorobiphenyl | decreases expression | 1 |
| manganese chloride | increases abundance, increases expression, affects cotreatment | 1 |
| N-acetyl-4-benzoquinoneimine | affects response to substance | 1 |
| coumarin | increases phosphorylation | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects cotreatment, decreases expression | 1 |
| perfluoro-n-nonanoic acid | increases expression | 1 |
| ICG 001 | increases expression | 1 |
| 2,2’,4,4’-tetrabromodiphenyl ether | increases expression | 1 |
| jinfukang | increases expression | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Decitabine | affects expression | 1 |
| Sunitinib | increases expression | 1 |
| Fulvestrant | affects cotreatment, increases methylation | 1 |
| Acetaminophen | increases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Atrazine | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.